Labeling
Both the actual content of Fosphenytoin Sodium and the content of Phenytoin Sodium, expressed in terms of phenytoin sodium equivalents, are stated prominently on the label.
(Official February 1, 2006)
Identification
A: Infrared Absorption 197K
Test specimen
Transfer a 5-mL aliquot of Injection to a 100-mL beaker, add 30 mL of acetone to form a white precipitate, and stir for 20 minutes using a magnetic stirrer. Filter in vacuum, and collect the precipitate using suitable filter paper. Allow to dry in vacuum for 15 minutes.
B:
The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Related compounds
Buffer solution, Mobile phase, Standard stock solution 1, Standard stock solution 2, and Chromatographic system
Proceed as directed in the Assay.
Standard solution
Use the Standard preparation, prepared as directed in the Assay.
Test solution
Use the Assay preparation, prepared as directed in the Assay.
Procedure
Inject a volume (about 40 µL) of the
Standard solution and the
Test solution into the chromatograph, record the chromatograms, and measure the peak areas. Calculate the percentages of phenytoin, phenytoin related compound A, phenytoin related compound B, and unknown impurities in each mL of Injection taken by the formula:
200,000(C/VL)(ri / rS),
in which
C is the concentration, in mg per mL, of the respective impurity in the
Standard solution; V is the volume, in mL, of the Injection taken to prepare the
Test solution; L is the labeled amount, in mg per mL, of fosphenytoin sodium in the Injection; and
ri and
rS are the individual peak responses of the impurities in the chromatograms obtained from the
Test solution and the
Standard solution, respectively: not more than 1.5% of phenytoin related compound B is found; not more than 0.2% of phenytoin is found; not more than 0.2% of phenytoin related compound A is found; not more than 0.1% of any individual unknown impurity is found; and not more than 2.0% total impurities is found.
[NOTEUse the peak area and concentration of the
USP Phenytoin RS in the
Standard solution as
rS and
C, respectively, to calculate the percentage of the unknown impurities.
]
Assay
Buffer solution
Dissolve about 8.2 g of monobasic potassium phosphate in 1 L of water. Adjust with 6 N potassium hydroxide solution to a pH of 6.5 ± 0.05.
Mobile phase
Prepare a filtered and degassed mixture of
Buffer solution, methanol, and acetonitrile (73:25:2). Make adjustments if necessary (see
System Suitability under
Chromatography 621).
Standard stock solution 1
Dissolve an accurately weighed quantity of
USP Fosphenytoin Sodium RS in methanol, and dilute quantitatively, and stepwise if necessary, with
Buffer solution to obtain a solution having a known concentration of about 0.75 mg per mL.
Standard stock solution 2
Dissolve an accurately weighed quantity of
USP Phenytoin RS, USP Phenytoin Related Compound A RS, and
USP Phenytoin Related Compound B RS in methanol, and dilute quantitatively, and stepwise if necessary, with methanol to obtain a solution having a known concentration of about 0.0075 mg per mL, 0.0075 mg per mL, and 0.015 mg per mL, respectively.
Standard preparation
Transfer 10.0 mL of Standard stock solution 1 and 5.0 mL of Standard stock solution 2 to a 50-mL volumetric flask. Dilute with Buffer solution to volume, and mix.
Assay preparation
Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to a 200-mL volumetric flask, dilute with methanol to volume, and mix. Transfer 5.0 mL of this solution to a 50-mL volumetric flask. Dilute with Buffer solution to volume, and mix.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 214-nm detector and a 4.6-mm × 15-cm column that contains packing L11. The flow rate is about 1.25 mL per minute. Chromatograph the
Standard preparation, and record the peak responses as directed for
Procedure: the relative retention times are about 0.3 for phenytoin related compound B, about 0.5 for phenytoin related compound A, 1.0 for fosphenytoin, and about 3.8 for phenytoin; the resolution,
R, between phenytoin related compound B and phenytoin related compound A is not less than 4.0; the column efficiency is not less than 2250 theoretical plates for the fosphenytoin peak; the tailing factor is not more than 1.8 for the fosphenytoin peak; and the relative standard deviation for replicate injections is not more than 1.0% for the fosphenytoin peak and not more than 5.0% for the phenytoin related compound B, phenytoin related compound A, and phenytoin peaks.
Procedure
Separately inject equal volumes (about 40 µL) of the
Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the peak areas for fosphenytoin. Calculate the quantity, in mg, of fosphenytoin sodium (C
16H
13N
2Na
2O
6P) in each mL of the Injection taken by the formula:
2000(C/V)(rU / rS),
in which
C is the concentration, in mg per mL, of
USP Fosphenytoin Sodium RS in the
Standard preparation; V is the volume, in mL, of the Injection taken to prepare the
Assay preparation; and
rU and
rS are the fosphenytoin peak areas obtained from the
Assay preparation and the
Standard preparation, respectively.